Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES CARNEGIE IN CONNECTION WITH HANSA MEDICAL’S RIGHTS ISSUE AND BLOCK SALE OF FARSTORPS GÅRD’S SHARES
Mandate

VINGE ADVISES CARNEGIE IN CONNECTION WITH HANSA MEDICAL’S RIGHTS ISSUE AND BLOCK SALE OF FARSTORPS GÅRD’S SHARES

March 09, 2015

Hansa Medical has resolved to carry out a rights issue of MSEK 246 before deduction of issue related costs. The rights issue is fully guaranteed through subscription undertakings and underwriting. The proceeds from the issue will be used to finance the company’s future research and development activities. In connection herewith, the company also announced that Hansa Medical’s former majority shareholder, Farstorps Gård, has sold some of its holding to certain Swedish and international institutional owners.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes.. The company’s shares are admitted to trading on Nasdaq First North in Stockholm.

Vinge advised Carnegie which is the financial adviser in connection with the rights issue and sale. The team consists of Peter Bäärnhielm, Dain Nevonen and Sabina Börjesson.   

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

 Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

 Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

 Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025